| Company Name: |
Guangzhou Isun Pharmaceutical Co., Ltd
|
| Tel: |
020-39119399 18927568969 |
| Email: |
isunpharm@qq.com |
| Products Intro: |
Product Name:NDB
CAS:1660153-08-1
Purity:98% (HPLC) Package:5MG; 25MG; 100MG; 1G
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Email: |
marketing1@energy-chemical.com |
| Products Intro: |
Product Name:NDB >=98% (HPLC)
CAS:1660153-08-1
Purity:NULL Package:25mg;5mg Remarks:NULL
|
NDB manufacturers
- NDB
-
- $99.00 / 1mg
-
2025-09-16
- CAS:1660153-08-1
- Min. Order:
- Purity: 98.94%
- Supply Ability: 10g
|
| Product Name: | NDB | | Synonyms: | NDB >=98% (HPLC);Benzamide, 2,6-dichloro-4-(dimethylamino)-N-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-N-(phenylmethyl)-;NDB | | CAS: | 1660153-08-1 | | MF: | C26H28Cl2N2O2 | | MW: | 471.42 | | EINECS: | | | Product Categories: | | | Mol File: | 1660153-08-1.mol |  |
| Boiling point | 628.6±55.0 °C(Predicted) | | density | 1.258±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: 10mg/mL, clear | | pka | 11.35±0.20(Predicted) | | form | Solid | | color | White to off-white |
| Uses | NDB is a selective human FXRα (hFXRα) antagonist that is effective in modulating transcription of FXRα downstream genes. NDB can be used in anti-diabetes research[1]. | | Biological Activity | NDB is a selective antagonist of human Farnesoid X receptor α (FXRα) th at effectively modulates FXRα down-stream genes. | | in vivo | NDB (24 mg/kg; intraperitoneal injection; once a day; for 4 weeks) efficiently decreases the gene expressions of phosphoenolpyruvate carboxykinase (PEPCK), glucose 6-phosphatase (G6-pase), small heterodimer partner, and BSEP in db/db mice[1]. | Animal Model: | Male C57BL/6J db/db mice (8 weeks of age)[1] | | Dosage: | 24 mg/kg | | Administration: | Intraperitoneal injection; once a day; for 4 weeks | | Result: | Decreased the gene expressions of PEPCK, G6-pase, small heterodimer partner, and BSEP.
|
| | References | [1] Xing Xu, et al. Structural Basis for Small Molecule NDB (N-Benzyl-N-(3-(tert-butyl)-4-hydroxyphenyl)-2,6-dichloro-4-(dimethylamino) Benzamide) as a Selective Antagonist of Farnesoid X Receptor α (FXRα) in Stabilizing the Homodimerization of the Receptor. J Biol Chem. 2015 Aug 7;290(32):19888-99. DOI:10.1074/jbc.M114.630475 |
| | NDB Preparation Products And Raw materials |
|